Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade N/A
- Symbol (ORPH)
- Company Orphazyme A/S
- Price $0.87
- Changes Percentage (0%)
- Change -$0
- Day Low $0.85
- Day High $0.96
- Year High $77.77
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 04/05/2022
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.83
- Trailing P/E Ratio -0.22691705790297
- Forward P/E Ratio -0.22691705790297
- P/E Growth -0.22691705790297
- Net Income $-633,246,000
Income Statement
Quarterly
Annual
Latest News of ORPH
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
UniQure's Fabry Disease Treatment Gets Orphan Drug Designation from FDA
UniQure received FDA orphan drug designation for AMT-191, a potential gene therapy for Fabry disease. This rare genetic disorder affects multiple body systems due to a gene deficiency. The company has...
By MarketWatch | 1 week ago -
Insider Buyers At Orpheus Uranium Sitting On AU$108k Profit
Insiders at Orpheus Uranium (ASX:ORP) remain optimistic despite a recent 15% stock price decline. Insider Paul Pheby made a notable AU$980k share purchase, indicating confidence. Insider ownership sta...
By Yahoo! Finance | 1 week ago -
Will Reeve Was Orphaned at 13 -- Here's Who Took Care of Him: 'Everybody Came Through' (Exclusive)
Gillian Telling, a Senior Reporter at People for 10 years, has also contributed to Entertainment Weekly, Rolling Stone, and Cosmopolitan. Will Reeve, son of Christopher and Dana Reeve, faced tremendou...
By PEOPLE.com | 2 weeks ago